Fluticasone Propionate And Salmeterol Powder
Product Images NDC 50090-4211

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 50090-4211). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure of the active ingredient fluticasone propionate as shown in the image, illustrating its molecular composition and arrangement of atoms representative of its chemical formula.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure diagram showing molecular formulas of two distinct molecules. The image likely represents the chemical structures of active ingredients, but no names or labels are visible on the diagram itself.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

A line graph showing the percentage change in FEV1 over 12 weeks and endpoint for four treatments: fluticasone propionate/salmeterol 100/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The x-axis represents weeks, and the y-axis shows percentage change in FEV1. The graph includes sample size data (N) for each treatment group at weeks 0, 6, 12, and endpoint.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

A line graph showing the percentage change in FEV1 over 12 hours after dosing on Day 1 baseline for four groups: fluticasone propionate/salmeterol 100/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph plots these changes hourly, with fluticasone propionate/salmeterol showing the highest increase, followed by salmeterol, fluticasone propionate, and placebo.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

A line graph showing the percentage change in FEV1 relative to Day 1 baseline over 12 hours. The graph compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The Fluticasone propionate/salmeterol group shows the highest increase, peaking around 40%, followed by Salmeterol and Fluticasone propionate groups, with placebo showing the least change.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

This line graph shows the percentage change in FEV1 (forced expiratory volume) over 24 weeks for three groups: Fluticasone propionate/salmeterol 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The y-axis represents percentage change in FEV1, and the x-axis shows weeks from 0 to 24 and the study endpoint. The graph also includes subject numbers (N) at various time points for each group.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line graph showing the percentage change in FEV1 over time for three groups: fluticasone propionate/salmeterol 250/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The x-axis represents time from Day 1 to Week 24, and the y-axis represents the percent change in FEV1. The combination treatment shows the highest improvement compared to fluticasone alone and placebo, which show lower and intermediate changes respectively. Sample sizes for each group at different time points are listed below the graph.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustrated diagram of a Fluticasone Propionate and Salmeterol DISKUS inhaler device showing labeled parts including the outer case, mouthpiece, lever, thumb grip, and counter. The label visible on the inhaler indicates a powder formulation with strengths of fluticasone propionate 100 mcg and salmeterol 50 mcg per inhalation in a 60 blister pack.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhalation device. An arrow indicates the direction to slide the device open, demonstrating the initial step for using the powder inhaler.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler device, with an arrow indicating the direction to slide the lever for use. The image demonstrates the proper operation of the DISKUS inhalation device.*

FDA Label Image

Ifu Figure D (Fp Sal Spl Graphic 11)

Illustration showing a woman using a respiratory inhaler device, demonstrating the proper technique of holding the inhaler and preparing to inhale medication. The inhaler appears to be a Diskus type, consistent with inhalation powder delivery.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

Black and white instructional image showing a woman using a Fluticasone Propionate and Salmeterol DISKUS inhalation device. She is holding the DISKUS to her mouth and appearing to inhale the powder medication through it.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

Instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. An arrow points horizontally to the left, indicating the direction to slide the inhaler cover open to prepare for use.*

FDA Label Image

Ifu Figure G (Fp Sal Spl Graphic 14)

Illustration showing a woman rinsing her mouth with water over a sink, likely demonstrating a step for oral care after using a respiratory inhalation powder like fluticasone propionate and salmeterol. A glass of water is visible beside the sink.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS 100 mcg/50 mcg powder inhalation device. The image shows a black and gray inhaler device labeled with the strength 100/50 mcg and indicating it contains 60 blisters. The label also includes spaces for pouch opened and use by dates.*

FDA Label Image

Label Image (Lbl500904211)

Fluticasone Propionate and Salmeterol DISKUS 100/50 MCG inhalation powder label from A-S Medication Solutions. It includes detailed drug identification, dosage form, storage instructions to keep between 68 and 77 degrees Fahrenheit, and packaging information indicating that each device contains one foil strip of 60 blisters.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.